Skip to main content

Table 2 Baseline characteristics divided by LGE status

From: T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides

 

LGE negative n = 21

LGE positive n = 16

p

Cardiovascular risk factors

 Diabetes

3 (14%)

4 (25%)

0.41

 Hypertension

8 (38%)

5 (31%)

0.67

 Smokinga

8 (38%)

5 (31%)

0.98

 Hyperlipidemia

2 (10%)

4 (25%)

0.21

 Family history of CVD

6 (29%)

5 (31%)

0.86

 Obesity (BMI ≥ 30 kg/m2)

6 (29%)

3 (19%)

0.49

Symptoms (multiple possible)

 Angina

2 (10%)

4 (25%)

0.21

 Dyspnea

8 (38%)

8 (50%)

0.55

 Palpitations

2 (10%)

2 (13%)

0.72

 Syncope

-

1 (6%)

0.25

 ECG abnormality

5 (24%)

6 (38%)

0.37

Years since diagnosis

  < 1

8 (38%)

4 (25%)

0.57

 1–4

5 (24%)

6 (38%)

0.63

 5–9

7 (33%)

4 (25%)

0.67

  ≥ 10

1 (5%)

2 (13%)

0.39

Disease Activity

 BVAS

4 (1–19)

6 (2.5–12.5)

0.91

Hematocrit

0.39 (0.32–0.41)

0.41 (0.38–0.44)

0.10

Medication

 Beta-blockers

5 (24%)

4 (25%)

0.93

 ARB

10 (48%)

4 (25%)

0.16

 ASA

-

5 (31%)

 

 CCB

6 (29%)

2 (13%)

0.24

 Statins

1 (5%)

2 (13%)

0.37

 Diuretics

4 (19%)

4 (25%)

0.66

 Steroids

21 (100%)

16 (100%)

0.16

 NSAID

1 (5%)

-

 

 Antibodies

2 (10%)

-

 

 Cyclophosphamide

11 (52%)

6 (38%)

0.67

 Azathioprine

1 (5%)

3 (19%)

0.18

 Methotrexate

2 (10%)

3 (19%)

0.42

  1. All values are n (%) or interquartile ranges. CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram, BVAS Birmingham vasculitis activity score, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug
  2. aCurrent or ever-smokers